Publication Name	World Journal of Gastroenterology
Manuscript ID	12802
Country	China

Received	2014-07-26 13:29
Peer-Review Started	2014-07-26 16:21
To Make the First Decision	2014-08-15 12:19
Return for Revision	2014-08-21 17:53
Revised	2014-09-08 20:50
Second Decision	2014-11-25 18:01
Accepted by Journal Editor-in-Chief	2014-11-26 02:24
Accepted by Executive Editor-in-Chief	2014-12-08 16:06
Articles in Press	2014-12-08 17:43
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-01-08 12:40
Typeset the Manuscript	2015-02-10 17:30
Publish the Manuscript Online	2015-03-09 15:58

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Retrospective Study
Article Title	Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients
Manuscript Source	Unsolicited Manuscript
All Author List	Dan-Hong Yang, Yuan-Jun Xie, Nian-Feng Zhao, Hong-Ying Pan, Ming-Wei Li and Hai-Jun Huang
Funding Agency and Grant Number
Corresponding Author	Hong-Ying Pan, MD, Director, De¬partment of Infectious Diseases, Zhejiang Provincial People’s Hospital, No. 158 Shangtang Road, Hangzhou 310014, Zhejiang Province, China. panhy2014@163.com
Key Words	Hepatitis B virus; Adefovir; Lamivudine; Tenofovir disoproxil fumarate; Viral resistance
Core Tip	We retrospectively assessed the efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy and continuous lamivudine (LAM) plus adefovir (ADV) combination therapy in LAM-resistant chronic hepatitis B (CHB) patients with suboptimal response to LAM plus ADV. Switching to TDF was effective and safe for LAM-resistant CHB patients and exerted stronger antiviral activity than continuous add-on therapy at week 48. Our findings suggest that suboptimal responders to LAM plus ADV should be switched as soon as possible to antiviral agents with higher potency, and TDF would be a viable option.
Publish Date	2015-03-09 15:58
Citation	Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753
URL	http://www.wjgnet.com/1007-9327/full/v21/i9/2746.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i9.2746

Full Article (PDF)	WJG-21-2746.pdf
Full Article (Word)	WJG-21-2746.doc
Manuscript File	12802-Review.docx
Answering Reviewers	12802-Answering reviewers.pdf
Copyright License Agreement	12802-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	12802-Language certificate.pdf
Peer-review Report	12802-Peer review(s).pdf
Scientific Misconduct Check	12802-CrossCheck.jpg
Scientific Editor Work List	12802-Scientific editor work list.pdf